What GPP 2022 is and who maintains it
GPP 2022, the 2022 update to the Good Publication Practice guidelines, sets out expectations for planning, conducting and reporting company-sponsored biomedical research responsibly and transparently. It was developed by a multidisciplinary group of authors associated with the International Society for Medical Publication Professionals and published in the Annals of Internal Medicine (DeTora et al., 2022).
The guidelines cover the roles and responsibilities of sponsors, investigators and professional medical writers; how to disclose funding, sponsorship and writing support; authorship criteria as applied to sponsor employees and contracted writers; data sharing and transparency commitments; and how to avoid selective or delayed publication of unfavourable results.
GPP has been revised several times since it was first published, reflecting changes in how sponsored research is conducted and reported, such as the growth of professional medical writing as a recognised specialism and the increasing use of multi-author, multi-site sponsored studies where disclosure questions are more complicated than in a single-centre academic study.
Why it exists
Company-sponsored research carries a structural tension that purely academic research does not: the sponsor has a commercial interest in how the results are presented, and may also employ or contract people, such as medical writers or statisticians, who are closely involved in producing the manuscript without necessarily appearing as named authors. Left unaddressed, this can produce manuscripts where the named authors' actual role is unclear, where a writer's substantial contribution goes unacknowledged, or where unfavourable findings are reported more slowly or less prominently than favourable ones.
GPP 2022 exists to set explicit expectations for exactly these situations: name the sponsor's role accurately, acknowledge professional writing support properly rather than hiding it, and apply the same authorship standard to everyone involved regardless of who employs them.
The guidelines also address a specific historical concern known as ghostwriting, where a sponsor-paid writer produces a substantial part of a manuscript without being named anywhere in it, and the named authors' actual contribution is unclear or minimal. GPP 2022 does not treat professional writing support itself as the problem; disclosed, properly acknowledged writing support under the named authors' direction is legitimate and common. The problem GPP 2022 targets is support that is concealed rather than disclosed.
Which situations it fits
GPP 2022 applies to any biomedical research publication where a commercial entity, such as a pharmaceutical, biotechnology, medical device or diagnostics company, funded or sponsored the study and is involved in some way in the resulting publication.
- An investigator-initiated trial funded by a company grant, with no further sponsor involvement in writing: GPP 2022 still expects the funding and the absence of further sponsor involvement to be stated explicitly.
- A company-led trial where company employees designed the study, analysed the data and contributed to the manuscript: those employees who meet the ICMJE authorship criteria should be listed as authors, with their affiliation and role disclosed.
- A manuscript drafted with the help of a professional medical writer paid by the sponsor: the writer's contribution, their employer, and who funded their involvement should all be disclosed in the acknowledgements.
- A collaborative academic-industry doctoral project: GPP 2022's principles on disclosure and author contribution are worth applying even where the specific guidelines are written with industry trials primarily in mind.
Where GPP 2022 does not apply
GPP 2022 does not replace the ICMJE authorship criteria; it applies them to the specific, recurring situations that arise in sponsored research, such as a sponsor statistician's role or a professional writer's contribution, rather than setting a different standard (International Committee of Medical Journal Editors, 2024). A study with no commercial sponsor at all does not need GPP 2022-specific disclosures, though the general principle of disclosing any relevant funding and role still applies under ICMJE.
GPP 2022 also does not set the technical reporting items a results section must contain; a sponsored randomised trial still needs to be reported fully against CONSORT (Hopewell et al., 2025), and a sponsored systematic review against the evidence-rating expectations frameworks such as GRADE set out (Guyatt et al., 2008). GPP 2022 adds transparency requirements specific to sponsorship on top of, not instead of, these reporting standards, which are themselves coordinated through the EQUATOR Network's wider library (Moher et al., 2008).
Why it matters
Readers of sponsored research need to be able to judge a study on its merits while knowing exactly what role the sponsor played, since sponsor involvement in study design, analysis or manuscript preparation is a legitimate fact a reader should be able to weigh, not something to be concealed. Where this kind of disclosure is incomplete, the broader publication ethics process described by COPE is what a journal falls back on to resolve the resulting concern after the fact (Committee on Publication Ethics, 2017); GPP 2022's detailed, sponsorship-specific expectations exist precisely to reduce how often that fallback is needed.
There is also a specific concern GPP 2022 addresses that is less about individual manuscripts and more about the published record as a whole: selective or delayed publication of unfavourable results from sponsored studies. If only favourable sponsored trials reach publication promptly, while less favourable ones are delayed or never published, the overall literature on a treatment can look more positive than the full body of evidence actually supports, a problem that affects systematic reviews and GRADE-rated evidence summaries drawing on that literature just as much as individual readers (Guyatt et al., 2008).
How it is applied in practice
This discipline is worth applying even to a small, single-centre collaboration, not only to large multi-site industry trials; the principle that every role is named accurately scales down just as well as it scales up.
Many pharmaceutical and biotechnology sponsors have internal publication policies built directly on GPP 2022, and professional medical writing agencies routinely reference it in their own codes of practice and client contracts. Journals in therapeutic areas with substantial industry funding commonly ask, in their submission checklist, whether a professional medical writer was involved and who funded that support, independent of whether the sponsor is itself a named entity in the paper.
A doctoral researcher collaborating with an industry sponsor, for example through a studentship co-funded by a company, should expect to be asked similar questions by their supervisor or institution well before submission: what role, if any, did the sponsor play in the analysis or interpretation, and was any writing support provided. Settling these questions early, in writing, avoids a late and awkward disagreement about how to describe the sponsor's role once the manuscript is close to submission.
In practice, the acknowledgements section of a sponsored manuscript following GPP 2022 typically names the funding source, states the sponsor's specific role (or explicitly that it had none beyond funding), names any professional medical writer and who paid for their time, and confirms that all authors had full access to the data or a defined subset with a stated reason.
An illustrative example
The passage below is a hypothetical illustration, not a quotation from a published manuscript.
| Element | Without GPP 2022 | With GPP 2022 |
|---|---|---|
| Funding statement | "This study was funded by Company X." | "This study was funded by Company X, which designed the study in collaboration with the academic investigators, had no role in data analysis, and reviewed the manuscript for factual accuracy before submission without influencing its conclusions." |
| Writing support | Not mentioned. | "Medical writing support was provided by [writer name], funded by Company X, under the direction of the authors, who had full control over content and approved the final version." |
| Sponsor employee authorship | "[Sponsor statistician] is not listed as an author." | "[Sponsor statistician], who led the statistical analysis and contributed to drafting the methods section, is listed as an author and disclosed as an employee of Company X." |
| Data access | Not addressed. | "All authors had access to the full dataset and the final decision to submit for publication; the raw data underlying the primary outcome are available on request." |
What to check before you submit
- Is the funding source, and the sponsor's specific role (or absence of one), stated explicitly?
- Is any professional medical writer named, with who funded and directed their work?
- Do sponsor employees who meet the ICMJE authorship criteria appear as authors, correctly affiliated (International Committee of Medical Journal Editors, 2024)?
- Is it stated who had access to the full data and who made the final decision to submit?
- Does the manuscript still meet the full technical reporting checklist for its design, such as CONSORT for a trial (Hopewell et al., 2025)?
- Official source: GPP 2022 (ismpp.org) .
Key takeaways
- GPP 2022 sets expectations for transparency and authorship in company-sponsored biomedical publications (DeTora et al., 2022).
- It exists because sponsored research involves roles, such as sponsor employees and professional writers, that general guidance can leave under-disclosed.
- It applies the ICMJE authorship criteria to these specific roles rather than replacing them (International Committee of Medical Journal Editors, 2024).
- It adds disclosure requirements on top of, not instead of, full technical reporting such as CONSORT (Hopewell et al., 2025) or GRADE-rated evidence summaries (Guyatt et al., 2008).
- Incomplete sponsorship disclosure, when it surfaces after publication, is typically resolved through the same COPE-guided process used for other ethics concerns (Committee on Publication Ethics, 2017).
